Category: Assay Development and Screening
Innoprot has developed a technology for multiplexing GPCR functional assays using fluorescent genetically encoded biosensors. This new technology comprises a family of fluorescent biosensors called “Nomad Biosensors®” that allow for the measurement of responses mediated by G proteins through their interactions with 2nd messenger transduction proteins and β-arrestins after GPCR activation. Different combinations of Nomad® Biosensors are co-expressed with a GPCR of interest within the same cell line for multiplexing functional assays and the identification of possible biased ligands. This approach allows in one single assay the measurement of the different signaling pathways involved in drug target activation. To validate Nomad technology, Protease activated receptor 2 (PAR2) Nomad® cell line has been developed to monitor β-arrestin recruitment & Ca++ concentration changes simultaneously in living cells. Thus, Endothelin Receptor B (ETBR) Nomad® Cell line has been developed to monitor cAMP & Ca++ concentration changes.
Aida Clarisa Salado– C.E.O., INNOPROT, Derio-Bizkaia, Pais Vasco, Spain
Derio-Bizkaia, Pais Vasco, Spain
Dr. Clarisa Salado holds a PhD in Biochemistry and has more than 18 years of experience in fields of pharmacology, drug screening and cancer. She has in the industry since 2002 working in Inbiomed and University of the Basque Country as Researcher and in the Biotechnology Company, Dominion Pharmakine as Biotechnology Division Director. She is currently the CEO of Innoprot.